Patient experience and burden of haemolytic disease of the foetus and newborn: a systematic review

Abstract Background Haemolytic disease of the foetus and newborn (HDFN) is an immune disorder driven by maternal alloimmunisation against foetal/newborn red blood cell antigens. HDFN can cause significant morbidity and mortality, with symptoms in the foetus ranging from mild anaemia to hydrops fetal...

Full description

Saved in:
Bibliographic Details
Main Authors: P. Maurice, J. McCallion, M. Fitzgibbon, J. N. Barthelmes, W. Karmous, E. J. Hardy, S. A. Mitchell, C. R. Mitchell, J. Lee, W. Noel, Andras Borsi, J. M. Jouannic
Format: Article
Language:English
Published: BMC 2025-02-01
Series:BMC Pregnancy and Childbirth
Subjects:
Online Access:https://doi.org/10.1186/s12884-025-07208-9
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1823861505483866112
author P. Maurice
J. McCallion
M. Fitzgibbon
J. N. Barthelmes
W. Karmous
E. J. Hardy
S. A. Mitchell
C. R. Mitchell
J. Lee
W. Noel
Andras Borsi
J. M. Jouannic
author_facet P. Maurice
J. McCallion
M. Fitzgibbon
J. N. Barthelmes
W. Karmous
E. J. Hardy
S. A. Mitchell
C. R. Mitchell
J. Lee
W. Noel
Andras Borsi
J. M. Jouannic
author_sort P. Maurice
collection DOAJ
description Abstract Background Haemolytic disease of the foetus and newborn (HDFN) is an immune disorder driven by maternal alloimmunisation against foetal/newborn red blood cell antigens. HDFN can cause significant morbidity and mortality, with symptoms in the foetus ranging from mild anaemia to hydrops fetalis. While in newborns, HDFN can lead to severe forms of neonatal hyperbilirubinaemia and kernicterus. This systematic review (SR) aimed to identify and summarise real-world evidence (RWE) related to the patient burden/experience and economic burden of HDFN. Methods Electronic database searches supplemented by handsearching of grey literature, were conducted to identify studies that reported the clinical patient burden/experience, and economic burden of HDFN in Europe, the Middle East, and Africa (EMEA). Data from eligible studies were summarised in a narrative synthesis due to heterogeneity between studies. Results A total of 26 relevant publications were identified for inclusion in the SR, consisting of one study that directly measured Health Related Quality of Life, 9 studies reporting on proxy outcomes for patient burden and 18 studies reporting on economic burden (this includes two double-counted studies reporting more than one outcome type). Neurodevelopment, academic development, behaviour and personality were assessed as proxy outcomes for patient burden given the limited identification of patient-reported outcome data. These studies suggested potential neurodevelopmental impairments in children with HDFN. Despite these indirect insights into patient burden, identified data were limited and results should be interpreted with consideration of the inherent heterogeneity in design and endpoints assessed across RWE studies. Economic burden data were primarily limited to healthcare resource use outcomes, with limited reported data on healthcare costs, it is difficult to draw notable conclusions on the true economic burden of HDFN. Conclusions The current SR provides a clear summary of the available evidence for the patient experience and economic burden of HDFN. While the limited evidence indicates that HDFN does confer a significant burden on patients, the review identifies the need for further well-powered and representative observational studies using well-defined outcome measures to aid a greater understanding of the burden and experience of HDFN. Trial registration The protocol for this systematic review was registered in PROSPERO CRD42022328444.
format Article
id doaj-art-cf129871393847afb32199b90d477f42
institution Kabale University
issn 1471-2393
language English
publishDate 2025-02-01
publisher BMC
record_format Article
series BMC Pregnancy and Childbirth
spelling doaj-art-cf129871393847afb32199b90d477f422025-02-09T12:59:15ZengBMCBMC Pregnancy and Childbirth1471-23932025-02-0125112210.1186/s12884-025-07208-9Patient experience and burden of haemolytic disease of the foetus and newborn: a systematic reviewP. Maurice0J. McCallion1M. Fitzgibbon2J. N. Barthelmes3W. Karmous4E. J. Hardy5S. A. Mitchell6C. R. Mitchell7J. Lee8W. Noel9Andras Borsi10J. M. Jouannic11National Center for Perinatal Hemobiology - Fetal Medicine Department – Armand Trousseau Hospital, AP-HP. Sorbonne UniversitéJanssen-Cilag EMEAJanssen-Cilag EMEAJanssen-Cilag GmbHJanssen-Cilag EMEAMtech Access LtdMtech Access LtdMtech Access LtdJanssen-Cilag EMEAJanssen-Cilag EMEAJanssen-Cilag EMEANational Center for Perinatal Hemobiology - Fetal Medicine Department – Armand Trousseau Hospital, AP-HP. Sorbonne UniversitéAbstract Background Haemolytic disease of the foetus and newborn (HDFN) is an immune disorder driven by maternal alloimmunisation against foetal/newborn red blood cell antigens. HDFN can cause significant morbidity and mortality, with symptoms in the foetus ranging from mild anaemia to hydrops fetalis. While in newborns, HDFN can lead to severe forms of neonatal hyperbilirubinaemia and kernicterus. This systematic review (SR) aimed to identify and summarise real-world evidence (RWE) related to the patient burden/experience and economic burden of HDFN. Methods Electronic database searches supplemented by handsearching of grey literature, were conducted to identify studies that reported the clinical patient burden/experience, and economic burden of HDFN in Europe, the Middle East, and Africa (EMEA). Data from eligible studies were summarised in a narrative synthesis due to heterogeneity between studies. Results A total of 26 relevant publications were identified for inclusion in the SR, consisting of one study that directly measured Health Related Quality of Life, 9 studies reporting on proxy outcomes for patient burden and 18 studies reporting on economic burden (this includes two double-counted studies reporting more than one outcome type). Neurodevelopment, academic development, behaviour and personality were assessed as proxy outcomes for patient burden given the limited identification of patient-reported outcome data. These studies suggested potential neurodevelopmental impairments in children with HDFN. Despite these indirect insights into patient burden, identified data were limited and results should be interpreted with consideration of the inherent heterogeneity in design and endpoints assessed across RWE studies. Economic burden data were primarily limited to healthcare resource use outcomes, with limited reported data on healthcare costs, it is difficult to draw notable conclusions on the true economic burden of HDFN. Conclusions The current SR provides a clear summary of the available evidence for the patient experience and economic burden of HDFN. While the limited evidence indicates that HDFN does confer a significant burden on patients, the review identifies the need for further well-powered and representative observational studies using well-defined outcome measures to aid a greater understanding of the burden and experience of HDFN. Trial registration The protocol for this systematic review was registered in PROSPERO CRD42022328444.https://doi.org/10.1186/s12884-025-07208-9Haemolytic disease of the foetus and newbornSystematic reviewPatient burdenEconomic burden
spellingShingle P. Maurice
J. McCallion
M. Fitzgibbon
J. N. Barthelmes
W. Karmous
E. J. Hardy
S. A. Mitchell
C. R. Mitchell
J. Lee
W. Noel
Andras Borsi
J. M. Jouannic
Patient experience and burden of haemolytic disease of the foetus and newborn: a systematic review
BMC Pregnancy and Childbirth
Haemolytic disease of the foetus and newborn
Systematic review
Patient burden
Economic burden
title Patient experience and burden of haemolytic disease of the foetus and newborn: a systematic review
title_full Patient experience and burden of haemolytic disease of the foetus and newborn: a systematic review
title_fullStr Patient experience and burden of haemolytic disease of the foetus and newborn: a systematic review
title_full_unstemmed Patient experience and burden of haemolytic disease of the foetus and newborn: a systematic review
title_short Patient experience and burden of haemolytic disease of the foetus and newborn: a systematic review
title_sort patient experience and burden of haemolytic disease of the foetus and newborn a systematic review
topic Haemolytic disease of the foetus and newborn
Systematic review
Patient burden
Economic burden
url https://doi.org/10.1186/s12884-025-07208-9
work_keys_str_mv AT pmaurice patientexperienceandburdenofhaemolyticdiseaseofthefoetusandnewbornasystematicreview
AT jmccallion patientexperienceandburdenofhaemolyticdiseaseofthefoetusandnewbornasystematicreview
AT mfitzgibbon patientexperienceandburdenofhaemolyticdiseaseofthefoetusandnewbornasystematicreview
AT jnbarthelmes patientexperienceandburdenofhaemolyticdiseaseofthefoetusandnewbornasystematicreview
AT wkarmous patientexperienceandburdenofhaemolyticdiseaseofthefoetusandnewbornasystematicreview
AT ejhardy patientexperienceandburdenofhaemolyticdiseaseofthefoetusandnewbornasystematicreview
AT samitchell patientexperienceandburdenofhaemolyticdiseaseofthefoetusandnewbornasystematicreview
AT crmitchell patientexperienceandburdenofhaemolyticdiseaseofthefoetusandnewbornasystematicreview
AT jlee patientexperienceandburdenofhaemolyticdiseaseofthefoetusandnewbornasystematicreview
AT wnoel patientexperienceandburdenofhaemolyticdiseaseofthefoetusandnewbornasystematicreview
AT andrasborsi patientexperienceandburdenofhaemolyticdiseaseofthefoetusandnewbornasystematicreview
AT jmjouannic patientexperienceandburdenofhaemolyticdiseaseofthefoetusandnewbornasystematicreview